Revisions to Brazil's drug price framework are coming - what's included and what's missing? Our analysts provide th… https://t.co/8s17gnKCXf
Life after the patent cliff: What's next for generics?
As Indian generics producer Dr. Reddy's announced yesterday that they want to boost their involvement in proprietary drugs and biosimilar drugs development, I've been pondering what the patent cliff means for the generic industry and how it defines the strategic choices of manufacturers.
With an avalanche of patents for high-revenue drugs expiring in the last 3 years - take Lipitor (atorvarstatin), for example - or about to expire in the next couple of years, the patent cliff has presented a major boon for the generics industry. However, it also brings with it risks.
After the patent cliff, the number of blockbuster drugs reaching patent expiry will slow down and in many cases they will be biologics or more complicated molecules to copy. Bringing copies of biologics (known as biosimilars) to market is not nearly as straight-forward as it is to bring copies of small chemical drugs to market in terms of development work (and risk), cost and expertise required. And achieving a return on investment from biosimilars is likely to be delayed considering that their market penetration tends to be slower and there is still lack of clarity in terms of prescribing requirements and substitution. Life for generic manufacturers is likely to become tougher after the patent cliff.
So what is the industry doing to prepare itself for life after the patent cliff? I'm looking forward to getting the answer to this and other strategic questions in the generics industry when I attend the European Generic medicines Association (EGA) annual meeting in Madrid next week (25-27 June). Stay tuned for more insights after the EGA meeting.
- Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
- Will IRP upend Czech orphan drug reforms?
- Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
- Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
- Will physicians become more difficult to find in America?
- California's Medicaid pharmacy "carve-out" set to boost state's negotiating power, introduce IRP for drugs
- Trend towards HTA collaboration boosts need for data
- Barriers to market access for innovative medicines increase in the COVID era
Major changes to Czech P&R regulations for orphan and high-cost drugs set to expand access. What role will IRP play… https://t.co/bQcVCG5jut